Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

STRIDE investigator Marc Bonaca, MD, MPH, University of Colorado School of Medicine, highlights how the data could provide insight into peripheral artery disease and type 2 diabetes treatment options.

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

Among patients with diabetes and peripheral artery disease, semaglutide 1 mg increased walking distance vs. placebo, ...

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

Medically reviewed by Danielle Weiss, MD Diabetic macular edema (DME) is a leading cause of vision loss in people with ...

Mouse study reveals beneficial bacteria play crucial role in helping insulin-producing cells multiply. Exposure to ...

Marci Wright, certified diabetes educator at UT Health Tyler, said people who ages 35 and older should be screened for diabetes.

Policymakers should focus on both obesity prevention and better access to treatment for those already living with obesity.